NASDAQ:OMER - Nasdaq - US6821431029 - Common Stock - Currency: USD
9.18
-0.43 (-4.47%)
The current stock price of OMER is 9.18 USD. In the past month the price increased by 1.89%. In the past year, price increased by 122.82%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
PFE | PFIZER INC | 8.46 | 149.04B | ||
SNY | SANOFI-ADR | 13.58 | 136.54B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
ZTS | ZOETIS INC | 27.1 | 72.39B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Omeros Corp. operates as a biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 198 full-time employees. The company went IPO on 2009-10-08. The firm is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
OMEROS CORP
201 Elliott Avenue West
Seattle WASHINGTON 98119 US
CEO: Gregory A. Demopulos
Employees: 198
Company Website: https://www.omeros.com/
Investor Relations: https://investor.omeros.com/
Phone: 12066765000
The current stock price of OMER is 9.18 USD. The price decreased by -4.47% in the last trading session.
The exchange symbol of OMEROS CORP is OMER and it is listed on the Nasdaq exchange.
OMER stock is listed on the Nasdaq exchange.
10 analysts have analysed OMER and the average price target is 40.29 USD. This implies a price increase of 338.89% is expected in the next year compared to the current price of 9.18. Check the OMEROS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
OMEROS CORP (OMER) has a market capitalization of 531.98M USD. This makes OMER a Small Cap stock.
OMEROS CORP (OMER) currently has 198 employees.
OMEROS CORP (OMER) has a support level at 9.02 and a resistance level at 9.62. Check the full technical report for a detailed analysis of OMER support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
OMER does not pay a dividend.
OMEROS CORP (OMER) will report earnings on 2025-02-26, after the market close.
OMEROS CORP (OMER) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.31).
The outstanding short interest for OMEROS CORP (OMER) is 16.91% of its float. Check the ownership tab for more information on the OMER short interest.
ChartMill assigns a technical rating of 7 / 10 to OMER. When comparing the yearly performance of all stocks, OMER is one of the better performing stocks in the market, outperforming 94.73% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to OMER. OMER may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months OMER reported a non-GAAP Earnings per Share(EPS) of -2.31. The EPS decreased by -821.88% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -42.93% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 80% to OMER. The Buy consensus is the average rating of analysts ratings from 10 analysts.